Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline Pharmaceuticals Limited ( (IN:GLAXO) ) just unveiled an announcement.
GlaxoSmithKline Pharmaceuticals Limited has concluded a postal ballot process conducted via remote e-voting to seek shareholder approval for key board and management changes. The process, held in compliance with the Companies Act and SEBI listing regulations, allowed members to vote electronically over a month-long window ending 8 April 2026.
Shareholders approved the appointment of Ronojit Biswas as a Director and as Whole-time Director and Chief Financial Officer, formalizing his dual role in governance and financial leadership. The company stated that the resolutions were passed based on the scrutinizer’s report, and detailed voting results and the report have been published on its website and that of KFintech for investor reference.
More about GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based pharmaceutical company focused on developing, manufacturing and marketing prescription medicines, vaccines and other healthcare products. The company operates in the healthcare and life sciences industry, serving domestic and international markets with a portfolio aligned to major therapeutic areas.
Average Trading Volume: 3,294
Technical Sentiment Signal: Buy
Current Market Cap: 394.9B INR
For a thorough assessment of GLAXO stock, go to TipRanks’ Stock Analysis page.